Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4764537
Max Phase: Preclinical
Molecular Formula: C17H15N5O3
Molecular Weight: 337.34
Molecule Type: Unknown
Associated Items:
ID: ALA4764537
Max Phase: Preclinical
Molecular Formula: C17H15N5O3
Molecular Weight: 337.34
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1cc2c(nc1C=O)N(C(=O)Nc1ccc(C#N)cn1)CCC2
Standard InChI: InChI=1S/C17H15N5O3/c1-25-14-7-12-3-2-6-22(16(12)20-13(14)10-23)17(24)21-15-5-4-11(8-18)9-19-15/h4-5,7,9-10H,2-3,6H2,1H3,(H,19,21,24)
Standard InChI Key: HONCQYFCOPAEKF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 337.34 | Molecular Weight (Monoisotopic): 337.1175 | AlogP: 2.15 | #Rotatable Bonds: 3 |
Polar Surface Area: 108.21 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.95 | CX Basic pKa: 1.51 | CX LogP: 2.31 | CX LogD: 2.31 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.86 | Np Likeness Score: -1.39 |
1. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P. (2020) Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4., 63 (21.0): [PMID:32930584] [10.1021/acs.jmedchem.0c01019] |
Source(1):